文献速递心脏核医学

骨显像诊断心脏转甲状腺素蛋白相关淀粉样变性的诊断准确性:一项双变量Meta分析

Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-23

该系统综述与双变量Meta分析纳入6项研究共529例患者,评估骨显像诊断心脏ATTR的准确性,汇总敏感度92.2%(95%CI 89-95%)、特异度95.4%(95%CI 77-99%)、LR+ 7.02(95%CI 3.42-14.4)、LR- 0.09(95%CI 0.06-0.14)、DOR 81.6(95%CI 44-153)。作者结论认为锝标记骨显像在心脏ATTR无创评估中具有很高的诊断准确性。

要点

  • 骨显像诊断心脏ATTR汇总敏感度92.2%、特异度95.4%。
  • 汇总LR+ 7.02、LR- 0.09、DOR 81.6。
  • 纳入6项研究共529例患者,研究间存在轻度异质性。

核心结论

  • 基于证据的数据表明,使用锝标记放射性示踪剂的骨显像在心脏ATTR的无创评估中具有很高的诊断准确性。

研究设计与样本

  • 系统综述与双变量Meta分析,计算机文献检索截至2017年11月30日,最终纳入6项关于心脏ATTR骨显像的研究,共529例患者。

主要发现

  • 骨显像诊断心脏ATTR的汇总敏感度为92.2%(95%CI 89-95%)。
  • 汇总特异度为95.4%(95%CI 77-99%)。
  • 汇总LR+为7.02(95%CI 3.42-14.4),LR-为0.09(95%CI 0.06-0.14)。
  • 汇总DOR为81.6(95%CI 44-153)。
  • 所选研究间存在轻度异质性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所选研究间存在轻度异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cardiac transthyretin-related amyloidosis (ATTR) is a progressive and fatal cardiomyopathy. The diagnosis of this disease is frequently delayed or missed due to the limited specificity of echocardiography. An increasing amount of data in the literature demonstrate the ability of bone scintigraphy with bone-seeking radiopharmaceuticals to detect myocardial amyloid deposits, in particular in patients with ATTR. Therefore we performed a systematic review and bivariate meta-analysis of the diagnostic accuracy of bone scintigraphy in patients with suspected cardiac ATTR. METHODS: A comprehensive computer literature search of studies published up to 30 November 2017 on the role of bone scintigraphy in patients with ATTR was performed using the following search algorithm: (a) "amyloid" OR "amyloidosis" AND (b) "TTR" OR "ATTR" OR "transthyretin" AND (c) "scintigraphy" OR "scan" OR "SPECT" OR "SPET" OR "bone" OR "skeletal" OR "skeleton" OR "PYP" OR "DPD" OR "HMDP" OR "MDP" OR "HDP". Pooled sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR-) and diagnostic odds ratio (DOR) of bone scintigraphy were calculated. RESULTS: The meta-analysis of six selected studies on bone scintigraphy in cardiac ATTR including 529 patients provided the following results: sensitivity 92.2% (95% CI 89-95%), specificity 95.4% (95% CI 77-99%), LR+ 7.02 (95% CI 3.42-14.4), LR- 0.09 (95% CI 0.06-0.14), and DOR 81.6 (95% CI 44-153). Mild heterogeneity was found among the selected studies. CONCLUSION: Our evidence-based data demonstrate that bone scintigraphy using technetium-labelled radiotracers provides very high diagnostic accuracy in the non-invasive assessment of cardiac ATTR.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Treglia G, Glaudemans AWJM, Bertagna F, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018. PMID: 29687207. doi:10.1007/s00259-018-4013-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。